Monte Rosa Therapeutics, Inc. (GLUE) Q2 2024 Earnings
GLUE·Reported August 8, 2024·Before market open
Monte Rosa Therapeutics, Inc. reported Q2 2024 revenue of $4.7M, beat analyst consensus of $1.3M by $3.3M. Diluted EPS came in at $-0.43, beat the $-0.54 consensus by $0.11.
Revenue
$4.7Mbeat by $3.3M
Consensus: $1.3MDiluted EPS
$-0.43beat by $0.11
Consensus: $-0.54
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q2 2024 Earnings FAQ
Common questions about Monte Rosa Therapeutics, Inc.'s Q2 2024 earnings report.
Monte Rosa Therapeutics, Inc. (GLUE) reported Q2 2024 earnings on August 8, 2024 before market open.
Monte Rosa Therapeutics, Inc. reported revenue of $4.7M and diluted EPS of $-0.43 for Q2 2024.
Revenue beat the consensus estimate of $1.3M by $3.3M. EPS beat the consensus estimate of $-0.54 by $0.11.